St. Louis, Missouri (PRWEB) November 25, 2014
As a personal injury law firm with a focus on defective drug law, Carey Danis & Lowe have remained abreast of the news circulating on the topic of testosterone gel and testosterone-replacement therapy as they relate to patient health and safety. Testosterone gels have been placed under increased scrutiny over the past year, in large part due to a study published in the Journal of the American Medical Association (JAMA) in November 2013 whose findings showed an increase in the risk of heart attack and stroke in study participants who used testosterone.
Carey Danis & Lowe contends that, perhaps in response to the JAMA study, the Food and Drug Administration (FDA) recently made steps to address testosterone gel safety through appointing an advisory panel. This special panel of experts released their recommendations to the FDA in September 2014.
According to an article published by the Wall Street Journal in late October 2014, the panel recommended that the FDA complete two actions, the first to order drug makers to conduct studies on their particular testosterone products as they relate to cardiovascular health, and the second, to update testosterone product labeling to reflect the reality that extensive research does not exist validating the safety of testosterone products to treat low testosterone.*
The recommendations of the FDA panel introduce the right course of action, say Carey Danis & Lowe, defective drug lawyers. It is important to test testosterone gel and other testosterone products to better understand their impact on heart health. Furthermore, updating the product labeling is vital in providing healthcare providers and patients with the most up-to-date information on the safety of testosterone products, so that they can make informed health decisions.
In addition to staying current on the FDA’s handling of testosterone gel, the legal team and medical professionals at Carey Danis & Lowe are also following the testosterone gel litigation taking place in a federal court in Illinois (U.S. District Court for the Northern District of Illinois, In re: Testosterone Replacement Therapy Product Liability Litigation, MDL no. 2545). As the St. Louis law firm provides legal assistance and representation to individuals who claim to have been injured by testosterone gel, Carey Danis & Lowe delivers their expert analysis on timely topics for the benefit of anyone interested in defective drug law and news.
Carey Danis & Lowe is available to review legal options, compensation eligibility, and health concerns with those who claim injury from testosterone gel products.
Carey Danis & Lowe can be reached by phone at 800.721.2519.
Carey Danis & Lowe is a plaintiff’s litigation firm based in St. Louis, Missouri. Carey Danis & Lowe specializes in defective drug and pharmaceutical litigation and class action lawsuits. The Carey Danis & Lowe team is comprised of experienced attorneys working alongside knowledgeable and professional staff that includes medical doctors, nurses, and information technology specialists. Contact Carey Danis & Lowe at 800.721.2519 for more information about our legal services.
Wall Street Journal, “In Men’s Fight Against Aging, How Much Risk to Take?”, Melinda Beck, October 27, 2014: http://bit.ly/wsj-testosterone-replacement-therapy